COMBINATION THERAPY FOR TREATING CANCER
A method of treating cancer or cancer metastasis comprising administering to a patient in need thereof a therapeutically effective amount of one or more anticancer agent selected from the group consisting of chemotherapy, an immunotherapy, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63 Cu, 64 Zn, 66 Zn, and 85 Rb, wherein said isotope is enriched to exceed 99% atomic mass.
1 . A method of treating a primary melanoma cancer with a combination therapy comprising administering to a patient in need thereof:
(i) a therapeutically effective amount of one or more anticancer agents selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and
(ii) a therapeutically effective amount of at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63 Cu, 64 Zn, 66 Zn, and 85 Rb, wherein said isotope is enriched to exceed 99% atomic mass;
wherein said anti-cancer agent(s) are known to be effective against primary melanoma cancer.
2 . The method of claim 1 , wherein said isotope selective modulator is administered prior to, concurrently with, or sequentially to administering said one or more cancer therapies.
3 . The method of claim 1 , wherein said isotope selective modulator is administered intravenously.
4 . The method of claim 1 , wherein said isotope selective modulator is administered intratumorally.
5 . The method of claim 1 , wherein said isotope selective modulator is optionally administered in combination with at least one amino acid enriched to at least 90% L-enantiomer, a flavonoid, a carotenoid, or a polyphenol.
6 . A method of treating a metastatic melanoma cancer with a combination therapy comprising administering to a patient in need thereof:
(i) a therapeutically effective amount of one or more anti-cancer agents selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and
(ii) a therapeutically effective amount of at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63 Cu, 64 Zn, 66 Zn, and 85 Rb, wherein said isotope is enriched to exceed 99% atomic mass;
wherein said anti-cancer agent(s) are known to be effective against said metastatic melanoma cancer.
7 . The method of claim 6 , wherein said isotope selective modulator is administered prior to, concurrently with, or sequential to administering said one or more cancer therapies.
8 . The method of claim 6 , wherein said isotope selective modulator is administered intravenously.
9 . The method of claim 6 , wherein said isotope selective modulator is administered intratumorally.
10 . The method of claim 6 , wherein said isotope selective modulator is optionally administered in combination with at least one amino acid enriched to at least 90% L-enantiomer, a flavonoid, a carotenoid, or a polyphenol.